Brigitte C. Widemann
Brigitte C. Widemann is a renowned oncologist and medical researcher specializing in the study and treatment of neurofibromatosis. She currently serves as the Chief of the Pediatric Oncology Branch at the National Cancer Institute (NCI), a part of the National Institutes of Health (NIH).
Early Life and Education[edit | edit source]
Brigitte C. Widemann was born and raised in Germany. She completed her undergraduate studies in biology and chemistry before moving to the United States for her medical education. She earned her medical degree from the University of Pennsylvania School of Medicine.
Career[edit | edit source]
Following her graduation, Widemann completed her residency in pediatrics at the Children's Hospital of Philadelphia. She then pursued a fellowship in pediatric oncology at the National Cancer Institute.
In her role as the Chief of the Pediatric Oncology Branch at the NCI, Widemann leads a team of researchers and clinicians dedicated to improving the lives of children and young adults with cancer and genetic tumor predisposition syndromes. Her research primarily focuses on the development of new therapies for patients with neurofibromatosis type 1 (NF1), a genetic disorder that causes tumors to form on nerve tissue.
Research and Contributions[edit | edit source]
Widemann's research has led to significant advancements in the understanding and treatment of neurofibromatosis. She has been instrumental in the development of selumetinib, a drug that has shown promise in shrinking tumors in children with NF1. Her work has been published in numerous peer-reviewed medical journals and she is often invited to speak at international conferences on pediatric oncology and neurofibromatosis.
Awards and Recognition[edit | edit source]
Over the course of her career, Widemann has received numerous awards and recognition for her contributions to the field of pediatric oncology. These include the NIH Director's Award and the Distinguished Clinical Teacher Award from the NIH Clinical Center.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
